Beta Blockers May Also Help Lung Cancer Patients Live Longer.
New investigate suggests that beta blockers, medications that are employed to control blood put the screws on and heart rhythms, may also help lung cancer patients live longer. The researchers found that patients with non-small-cell lung cancer being treated with emission lived 22 percent longer if they were also taking these drugs. "These findings were the first, to our knowledge, demonstrating a survival advance associated with the use of beta blockers and diffusion therapy for lung cancer," said lead researcher Dr Daniel Gomez, an aide professor in the department of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston.
So "The results mean that there may be another mechanism, largely unexplored, that could potentially drop the rates of tumor spread in patients with this very aggressive disease". The story was published Jan 9, 2013 in the Annals of Oncology. For the study, Gomez's body compared the outcomes of more than 700 patients undergoing radiation therapy for lung cancer.
The investigators found that the 155 patients taking beta blockers for focus problems lived an average of almost two years, compared with an usual of 18,6 months for patients not taking these drugs. The findings held even after adjusting for other factors such as age, originate of the disease, whether or not chemotherapy was given at the same time, presence of chronic obstructive pulmonary infection and aspirin use, the researchers noted. Beta blockers also improved survival without the disease spreading to other parts of the body and survival without the disorder recurring.
Showing posts with label survival. Show all posts
Showing posts with label survival. Show all posts
Sunday 16 February 2020
Sunday 5 January 2020
A Promising Way To Treat Specific Lymphoma
A Promising Way To Treat Specific Lymphoma.
Researchers have identified a gene transmutation that may offering a target for new treatments for a type of lymphoma. The set found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as weighty B cell lymphoma. The MYD88 gene encodes a protein that is crucial for routine immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of virulent cells. A subgroup of the large B cell lymphoma that has a dismally crude cure rate - known as the activated B cell-like (ABC) subtype - appears especially susceptible to the gene.
Researchers have identified a gene transmutation that may offering a target for new treatments for a type of lymphoma. The set found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as weighty B cell lymphoma. The MYD88 gene encodes a protein that is crucial for routine immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of virulent cells. A subgroup of the large B cell lymphoma that has a dismally crude cure rate - known as the activated B cell-like (ABC) subtype - appears especially susceptible to the gene.
Thursday 26 December 2019
A New Drug For The Treatment Of Skin Cancer Increases The Survival Of Patients
A New Drug For The Treatment Of Skin Cancer Increases The Survival Of Patients.
Scientists intend that a creative drug to bonus melanoma, the first in its class, improved survival by 68 percent in patients whose disease had mushrooming from the skin to other parts of the body. This is big news in the field of melanoma research, where survival rates have refused to budge, in defiance of numerous efforts to come up with an effective treatment for the increasingly common and disastrous skin cancer over the past three decades. "The last time a drug was approved for metastatic melanoma was 12 years ago, and 85 percent of plebeians who take that numb have no benefit, so finding another drug that is going to have an impact, and even a bigger impact than what's out there now, is a notable improvement for patients," said Timothy Turnham, executive director of the Melanoma Research Foundation in Washington, DC.
The findings on the drug, called ipilimumab, were reported simultaneously Saturday at the annual union of the American Society of Clinical Oncology (ASCO) in Chicago and in the June 5 online child of the New England Journal of Medicine. Ipilimumab is the start in a new class of targeted T-cell antibodies, with possible applications for other cancers as well.
Both the incidence of metastatic melanoma and the termination rate have risen during the past 30 years, and patients with advanced disease typically have little treatment options. "Ipilimumab is a human monoclonal antibody directed against CTLA-4, which is on the surface of T-cells which struggle infection ," explained lead study author Dr Steven O'Day, number one of the melanoma program at the Angeles Clinic and Research Institute in Los Angeles. "CTL is a very high-ranking break to the immune system, so by blocking this break with ipilimumab, it accelerates and potentiates the T-cells. And by doing that they become activated and can go out and smother the cancer.
Scientists intend that a creative drug to bonus melanoma, the first in its class, improved survival by 68 percent in patients whose disease had mushrooming from the skin to other parts of the body. This is big news in the field of melanoma research, where survival rates have refused to budge, in defiance of numerous efforts to come up with an effective treatment for the increasingly common and disastrous skin cancer over the past three decades. "The last time a drug was approved for metastatic melanoma was 12 years ago, and 85 percent of plebeians who take that numb have no benefit, so finding another drug that is going to have an impact, and even a bigger impact than what's out there now, is a notable improvement for patients," said Timothy Turnham, executive director of the Melanoma Research Foundation in Washington, DC.
The findings on the drug, called ipilimumab, were reported simultaneously Saturday at the annual union of the American Society of Clinical Oncology (ASCO) in Chicago and in the June 5 online child of the New England Journal of Medicine. Ipilimumab is the start in a new class of targeted T-cell antibodies, with possible applications for other cancers as well.
Both the incidence of metastatic melanoma and the termination rate have risen during the past 30 years, and patients with advanced disease typically have little treatment options. "Ipilimumab is a human monoclonal antibody directed against CTLA-4, which is on the surface of T-cells which struggle infection ," explained lead study author Dr Steven O'Day, number one of the melanoma program at the Angeles Clinic and Research Institute in Los Angeles. "CTL is a very high-ranking break to the immune system, so by blocking this break with ipilimumab, it accelerates and potentiates the T-cells. And by doing that they become activated and can go out and smother the cancer.
Tuesday 10 December 2019
The Researchers Have Found A Way To Treat Ovarian Cancer
The Researchers Have Found A Way To Treat Ovarian Cancer.
By counting the enumerate of cancer-fighting vaccinated cells inside tumors, scientists mean they may have found a way to predict survival from ovarian cancer. The researchers developed an theoretical method to count these cells, called tumor-infiltrating T lymphocytes (TILs), in women with at daybreak stage and advanced ovarian cancer. "We have developed a standardizable method that should one day be at one's fingertips in the clinic to better inform physicians on the best course of cancer therapy, therefore improving treatment and patient survival," said lead actor researcher Jason Bielas, at the Fred Hutchinson Cancer Research Center, in Seattle.
The check may have broader implications beyond ovarian cancer and be useful with other types of cancer, the observe authors suggested. In their current work with ovarian cancer patients, the researchers "demonstrated that this routine can be used to diagnose T-cells quickly and effectively from a blood sample," said Bielas, an confidant member in human biology and public health sciences. The report was published online Dec 4, 2013 in Science Translational Medicine.
The researchers developed the probe to quantify TILs, identify their frequency and develop a system to determine their ability to clone themselves. This is a condition of measuring the tumor's population of immune T-cells. The test mechanism by collecting genetic information of proteins only found in these cells. "T-cell clones have unique DNA sequences that are comparable to offshoot barcodes on items at the grocery store.
Our technology is comparable to a barcode scanner". The technique, called QuanTILfy, was tested on tumor samples from 30 women with ovarian cancer whose survival ranged from one month to about 10 years. Bielas and colleagues looked at the horde of TILs in the tumors, comparing those numbers to the women's survival. The researchers found that higher TIL levels were linked with better survival.
By counting the enumerate of cancer-fighting vaccinated cells inside tumors, scientists mean they may have found a way to predict survival from ovarian cancer. The researchers developed an theoretical method to count these cells, called tumor-infiltrating T lymphocytes (TILs), in women with at daybreak stage and advanced ovarian cancer. "We have developed a standardizable method that should one day be at one's fingertips in the clinic to better inform physicians on the best course of cancer therapy, therefore improving treatment and patient survival," said lead actor researcher Jason Bielas, at the Fred Hutchinson Cancer Research Center, in Seattle.
The check may have broader implications beyond ovarian cancer and be useful with other types of cancer, the observe authors suggested. In their current work with ovarian cancer patients, the researchers "demonstrated that this routine can be used to diagnose T-cells quickly and effectively from a blood sample," said Bielas, an confidant member in human biology and public health sciences. The report was published online Dec 4, 2013 in Science Translational Medicine.
The researchers developed the probe to quantify TILs, identify their frequency and develop a system to determine their ability to clone themselves. This is a condition of measuring the tumor's population of immune T-cells. The test mechanism by collecting genetic information of proteins only found in these cells. "T-cell clones have unique DNA sequences that are comparable to offshoot barcodes on items at the grocery store.
Our technology is comparable to a barcode scanner". The technique, called QuanTILfy, was tested on tumor samples from 30 women with ovarian cancer whose survival ranged from one month to about 10 years. Bielas and colleagues looked at the horde of TILs in the tumors, comparing those numbers to the women's survival. The researchers found that higher TIL levels were linked with better survival.
Saturday 16 November 2019
Children Survive After A Liver Transplant
Children Survive After A Liver Transplant.
White children in the United States have higher liver move survival rates than blacks and other minority children, a untrained meditate on finds. Researchers looked at 208 patients, aged 22 and younger, who received a liver resettle at Children's Hospital of Atlanta between January 1998 and December 2008. Fifty-one percent of the patients were white, 35 percent were black, and 14 percent were other races.
At one, three, five and 10 years after transplant, implement and unfailing survival was higher amid white recipients than among minority recipients, the investigators found. The 10-year unit survival rate was 84 percent among whites, 60 percent among blacks and 49 percent to each other races. The 10-year patient survival rate was 92 percent for whites, 65 percent for blacks and 76 percent mid other races.
White children in the United States have higher liver move survival rates than blacks and other minority children, a untrained meditate on finds. Researchers looked at 208 patients, aged 22 and younger, who received a liver resettle at Children's Hospital of Atlanta between January 1998 and December 2008. Fifty-one percent of the patients were white, 35 percent were black, and 14 percent were other races.
At one, three, five and 10 years after transplant, implement and unfailing survival was higher amid white recipients than among minority recipients, the investigators found. The 10-year unit survival rate was 84 percent among whites, 60 percent among blacks and 49 percent to each other races. The 10-year patient survival rate was 92 percent for whites, 65 percent for blacks and 76 percent mid other races.
A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer
A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer.
A novel chemotherapy anaesthetize made from a Davy Jones's locker sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The encouraging finding on the drug, known as eribulin, was presented Sunday at the annual assembly of the American Society of Clinical Oncology in Chicago. "We have a major need for fresh therapies," noted study author Dr Christopher Twelves. "We see a statistically significant promote in overall survival in a situation where we rarely see this sort of improvement".
So "Eribulin targets the mechanisms by which the cells divide, which is novel from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and make a beeline for of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to come into either eribulin or a "treatment of physician's choice," the persist because there isn't a standard care for this type of cancer. In almost all cases, it was another chemotherapy.
The study included women who had already been treated extensively for their cancer, with the norm patient already having undergone four chemotherapies. The researchers blast a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin heap at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially substantiate eribulin as a new and effective treatment for women with heavily pretreated bosom cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.
Also featured at the intersection Sunday, Italian researchers report that liver biopsies can expose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor significance or HER2 status. These tumor properties often dictate the type of treatment a woman receives, intention that some women may benefit from switching therapy if the characteristics of their cancer change.
A novel chemotherapy anaesthetize made from a Davy Jones's locker sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The encouraging finding on the drug, known as eribulin, was presented Sunday at the annual assembly of the American Society of Clinical Oncology in Chicago. "We have a major need for fresh therapies," noted study author Dr Christopher Twelves. "We see a statistically significant promote in overall survival in a situation where we rarely see this sort of improvement".
So "Eribulin targets the mechanisms by which the cells divide, which is novel from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and make a beeline for of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to come into either eribulin or a "treatment of physician's choice," the persist because there isn't a standard care for this type of cancer. In almost all cases, it was another chemotherapy.
The study included women who had already been treated extensively for their cancer, with the norm patient already having undergone four chemotherapies. The researchers blast a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin heap at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially substantiate eribulin as a new and effective treatment for women with heavily pretreated bosom cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.
Also featured at the intersection Sunday, Italian researchers report that liver biopsies can expose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor significance or HER2 status. These tumor properties often dictate the type of treatment a woman receives, intention that some women may benefit from switching therapy if the characteristics of their cancer change.
Sunday 3 December 2017
New Methods Of Treatment Of Ovarian Cancer
New Methods Of Treatment Of Ovarian Cancer.
Women with advanced ovarian cancer who walk off hotheaded chemotherapy directly into their stomach area may live at least one year longer than women who pick up standard intravenous chemotherapy, a new study says. But this survival work may come at the expense of more side effects. "The long-term benefits are fairly significant," said study author Dr Devansu Tewari, director of gynecologic oncology at the Southern California Permanente Medical Group, in Orange County. "There is no learn of ovarian cancer treatments that has shown a greater survival advantage".
Intraperitoneal chemotherapy involves bathing the abdominal field with chemotherapy agents. By contrast, intravenous (IV) chemotherapy is delivered throughout the body via the bloodstream. The US National Cancer Institute currently recommends intraperitoneal remedy for women with ovarian cancer who have had top surgery to erase the tumor.
The 10-year follow-up data from two studies of nearly 900 women with advanced ovarian cancer will be presented Saturday at the annual get-together of the Society of Gynecologic Oncology, in Los Angeles. In 2013, more than 22000 American women will be diagnosed with ovarian cancer, and more than 14000 will want from the disease, according to the US National Cancer Institute. There are no initial screening tests for ovarian cancer, which is why it is often diagnosed when the cancer has already landholding independent of the ovaries.
For this reason, survival rates tend to be very low. In the new study, women who received the intraperitoneal care were 17 percent more likely to survive longer than those who got IV chemotherapy. On average, women in the intraperitoneal congregation survived for more than five years, while those who received IV chemotherapy survived for about four years, the deliberate over found. But survival benefits aside, intraperitoneal chemotherapy does take counsel a greater risk of side effects - such as abdominal anguish and numbness in the hands and feet - and not all women can tolerate this high concentration of cancer-killing drugs.
The drugs are also occupied more slowly, providing more exposure to the medicine. The same properties that make the intraperitoneal remedial programme more effective likely play a role in causing more side effects, the researchers said. In general, six cycles of intraperitoneal chemotherapy are recommended, and can be given in inpatient or outpatient settings. The more cycles the women completed, the greater their survival advantage, the research showed.
Women with advanced ovarian cancer who walk off hotheaded chemotherapy directly into their stomach area may live at least one year longer than women who pick up standard intravenous chemotherapy, a new study says. But this survival work may come at the expense of more side effects. "The long-term benefits are fairly significant," said study author Dr Devansu Tewari, director of gynecologic oncology at the Southern California Permanente Medical Group, in Orange County. "There is no learn of ovarian cancer treatments that has shown a greater survival advantage".
Intraperitoneal chemotherapy involves bathing the abdominal field with chemotherapy agents. By contrast, intravenous (IV) chemotherapy is delivered throughout the body via the bloodstream. The US National Cancer Institute currently recommends intraperitoneal remedy for women with ovarian cancer who have had top surgery to erase the tumor.
The 10-year follow-up data from two studies of nearly 900 women with advanced ovarian cancer will be presented Saturday at the annual get-together of the Society of Gynecologic Oncology, in Los Angeles. In 2013, more than 22000 American women will be diagnosed with ovarian cancer, and more than 14000 will want from the disease, according to the US National Cancer Institute. There are no initial screening tests for ovarian cancer, which is why it is often diagnosed when the cancer has already landholding independent of the ovaries.
For this reason, survival rates tend to be very low. In the new study, women who received the intraperitoneal care were 17 percent more likely to survive longer than those who got IV chemotherapy. On average, women in the intraperitoneal congregation survived for more than five years, while those who received IV chemotherapy survived for about four years, the deliberate over found. But survival benefits aside, intraperitoneal chemotherapy does take counsel a greater risk of side effects - such as abdominal anguish and numbness in the hands and feet - and not all women can tolerate this high concentration of cancer-killing drugs.
The drugs are also occupied more slowly, providing more exposure to the medicine. The same properties that make the intraperitoneal remedial programme more effective likely play a role in causing more side effects, the researchers said. In general, six cycles of intraperitoneal chemotherapy are recommended, and can be given in inpatient or outpatient settings. The more cycles the women completed, the greater their survival advantage, the research showed.
Tuesday 13 October 2015
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives.
Researchers record they prolonged survival for some patients with advanced non-small room lung cancer, for whom the median survival is currently only about six months. One ruminate on discovered that an experimental sedate called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or brutally 40000 men and women worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited past it patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the time of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, arbitrator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million population worldwide. Sadly, it is our nation's - and our world's - foremost cancer".
The initial study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small chamber lung cancer with a specific mutation of the ALK gene, which makes that gene merge with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an unexceptional of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said lessons author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients competent nausea, vomiting and diarrhea but these camp effects eased over time. The fusion gene was first discovered to play a duty in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported economic ties to Pfizer.
Researchers record they prolonged survival for some patients with advanced non-small room lung cancer, for whom the median survival is currently only about six months. One ruminate on discovered that an experimental sedate called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or brutally 40000 men and women worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited past it patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the time of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, arbitrator of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million population worldwide. Sadly, it is our nation's - and our world's - foremost cancer".
The initial study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small chamber lung cancer with a specific mutation of the ALK gene, which makes that gene merge with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an unexceptional of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said lessons author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients competent nausea, vomiting and diarrhea but these camp effects eased over time. The fusion gene was first discovered to play a duty in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported economic ties to Pfizer.
Thursday 22 August 2013
A New Therapeutic Vaccine Against Prostate Cancer
A New Therapeutic Vaccine Against Prostate Cancer.
A newly approved curative prostate cancer vaccine won the validate Wednesday of a Medicare consultative committee, increasing the chances that Medicare will deserts for the drug. Officials from Medicare, the federal assurance program for the elderly and disabled, will believe the committee's vote when making a final decision on payment. Such a purposefulness is expected in several months, the Wall Street Journal reported bestvito. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per unfaltering and extends survival by about four months on average, according to results from clinical trials.
A boning up published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors uncompliant to authoritative hormonal treatment, compared with no treatment. And the psychoanalysis interested less toxicity than chemotherapy.
Provenge is a healthy (not preventive) vaccine made from the patient's own whey-faced blood cells. Once removed from the patient, the cells are treated with the stupefy and placed back into the patient. These treated cells then trigger an insusceptible answer that in turn kills cancer cells, leaving natural cells unharmed.
The vaccine is given intravenously in a three-dose outline delivered in two-week intervals. "The strategy of trying to harness the unsusceptible system to fight cancer has been something that commonalty have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of cure-all at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
A newly approved curative prostate cancer vaccine won the validate Wednesday of a Medicare consultative committee, increasing the chances that Medicare will deserts for the drug. Officials from Medicare, the federal assurance program for the elderly and disabled, will believe the committee's vote when making a final decision on payment. Such a purposefulness is expected in several months, the Wall Street Journal reported bestvito. The vaccine, called Provenge and made by the Dendreon Corp, costs $93000 per unfaltering and extends survival by about four months on average, according to results from clinical trials.
A boning up published in July in the New England Journal of Medicine found that the vaccine extended the lives of men with metastatic tumors uncompliant to authoritative hormonal treatment, compared with no treatment. And the psychoanalysis interested less toxicity than chemotherapy.
Provenge is a healthy (not preventive) vaccine made from the patient's own whey-faced blood cells. Once removed from the patient, the cells are treated with the stupefy and placed back into the patient. These treated cells then trigger an insusceptible answer that in turn kills cancer cells, leaving natural cells unharmed.
The vaccine is given intravenously in a three-dose outline delivered in two-week intervals. "The strategy of trying to harness the unsusceptible system to fight cancer has been something that commonalty have tried to attain for many years; this is one such strategy," study lead researcher Dr Philip Kantoff, a professor of cure-all at Harvard Medical School and a medical oncologist at the Dana-Farber Cancer Institute in Boston, told HealthDay.
Subscribe to:
Posts (Atom)